Ozempic Maker Novo Nordisk Sues Eli Lilly For Deceptive Advertising
Forbes
Last updated: July 22, 2026
Pharmaceutical giants Novo Nordisk and Eli Lilly are embroiled in a legal battle over advertising practices. Novo Nordisk, the maker of Ozempic, has sued Eli Lilly, accusing them of deceptive advertising related to their weight-loss drug.
- Novo Nordisk alleges that Eli Lilly has employed misleading tactics in its promotional materials for its diabetes and weight-loss medication, tirzepatide (Mounjaro/Zepbound).
- The lawsuit, filed in federal court, specifically claims that Eli Lilly is utilizing outdated or selectively presented clinical trial data in its advertising campaigns to make its drug appear more effective or have fewer side effects than is accurately represented.
- Novo Nordisk contends that these advertising practices by Eli Lilly are deceptive and potentially harm consumers by providing a skewed understanding of the medication's profile.
- The core of the dispute centers on the interpretation and presentation of scientific evidence in marketing efforts for competing weight-loss and diabetes treatments.
- The legal action highlights the intense competition within the pharmaceutical industry, particularly in the lucrative market for obesity and diabetes medications.
- This lawsuit could set a precedent for how pharmaceutical companies are allowed to advertise the efficacy and safety of their drugs, especially as new treatments gain traction.
